PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$162.79

11 Jun
2026

1.210

OPEN

$160.66

0.75%

HIGH

$163.22

294,740

LOW

$160.22

TARGET
$218.667 34.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 110.3 180.1 xxx
DPS (cps) xxx 55.0 66.2 xxx
EPS Growth xxx 39.1% 63.3% xxx
DPS Growth xxx 37.5% 20.3% xxx
PE Ratio xxx N/A 91.0 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 49.9% 36.7% xxx

Dividend yield today if purchased 3 years ago: 0.87%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.34

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 30.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx110.3
DPS All xxxxxxxxxxxxxxx55.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx246.0
Net Operating Cash Flow xxxxxxxxxxxxxxx118.9 M
Net Profit Margin xxxxxxxxxxxxxxx54.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx51.82 %
Return on Invested Capital xxxxxxxxxxxxxxx51.46 %
Return on Assets xxxxxxxxxxxxxxx38.65 %
Return on Equity xxxxxxxxxxxxxxx51.82 %
Return on Total Capital xxxxxxxxxxxxxxx70.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx69.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx209 M
Price To Book Value xxxxxxxxxxxxxxx115.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxxxxxxxx3.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

30/04/2026

1

Overweight

$200.00

22.86%

Morgan Stanley notes leading ASX software incumbents are not only exposed to AI-driven disruption, but are also well positioned to harness AI to their advantage.

In many cases, these firms may be better placed than new entrants, the analysts suggest, given their access to proprietary data, deep vertical expertise, scale and established distribution networks.

The broker introduces its Moat Framework, comprising 10 factors used to assess which companies can sustain differentiated value in an AI-driven landscape. This considers those best positioned to adapt, and where competitive advantages are most at risk of erosion.

Morgan Stanley's central conclusion is that while AI is lowering the cost of software development, it does not render all software free, nor does it eliminate the need for third-party vendors.

From among the broker's coverage, key preferred exposures include REA Group, WiseTech Global, CAR Group, Xero and Pro Medicus.

Least preferred are Appen, Airtasker and Megaport.

Overweight retained for Pro Medicus. Target $200. Industry View: Attractive.

FORECAST
Morgan Stanley forecasts a full year FY26 dividend of 55.60 cents and EPS of 139.10 cents.
Morgan Stanley forecasts a full year FY27 dividend of 73.60 cents and EPS of 184.10 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

25/03/2026

1

Upgrade to Buy from Hold

$145.03

-10.91%

Moelis upgrades Pro Medicus to Buy from Hold although acknowledges macro risks will overhang the stock in the near term while the long-term outlook is unchanged with strong growth rates likely continuing for a number of years.

The broker points out the share price since the first half result has fallen a further -6%, largely related to macro events that are beyond management's control.

The report also states it is important to note this is not a cyclical business and customers are largely insulated from the impacts of higher oil prices. Target is $145.03.

FORECAST
Moelis forecasts a full year FY26 dividend of 67.00 cents and EPS of 138.10 cents.
Moelis forecasts a full year FY27 dividend of 96.00 cents and EPS of 191.80 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: Australia’s Sh*t Sandwich

Jun 04 2026 - Rudi's View
2
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
3
Rudi’s View: Tech Is Back (Ahead Of Tax Loss Selling)

Jun 03 2026 - Rudi's View
4
Next Week At A Glance – 25-29 May 2026

May 22 2026 - Weekly Reports
5
Australian Broker Call *Extra* Edition – May 13, 2026

May 13 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
2
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
3
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
4
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
5
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
6
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
7
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
8
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
9
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
10
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia